Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly

Clinical Pharmacology and Therapeutics

Volumn 62, Issue 3, 1997, Pages 300-310

  Jorga, Karin M ^a   Sȩdek, Grzegorz ^a   Fotteler, Bärbel ^a   Zürcher, Gerhard ^a   Nielsen, Thorkild ^a   Aitken, John W ^a  

^a F Hoffmann La Roche ^*

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; DRUG METABOLITE; LEVODOPA; PLACEBO; TOLCAPONE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BIOAVAILABILITY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; ELECTROCARDIOGRAM; ENZYME INHIBITION; ERYTHROCYTE; FEMALE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO; VOMITING;

ADMINISTRATION, ORAL; AGED; ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; BENZOPHENONES; CATECHOL O-METHYLTRANSFERASE; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ENZYME INHIBITORS; ERYTHROCYTES; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; NITROPHENOLS;

EID: 0030876269     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90033-3     Document Type: Article

References (10)

1. Hornykiewicz O. Brain neurotransmitter changes in Parkinson's disease. In: Marsden CD, Fahn S, editors. Movement disorders. London: Butterworth Scientific; 1982. p. 41-58.
2. Calne DB. Treatment of Parkinson's disease. N Engl J Med 1993;329:1021-7.
3. LeWitt PA. Treatment strategies for extension of levodopa effect. Neurol Clin 1992;10:511-26.
4. Männistö PT, Kaakkola S. New selective COMT inhibitors: useful adjuncts for Parkinson's disease? Trends Pharmacol Sci 1989;10:54-6.
5. LeWitt P. The pharmacology of levodopa in the treatment of Parkinson's disease: an update. In: Calne D, editor. Drugs for the treatment of Parkinson's disease. Berlin: Springer Verlag; 1989. p. 325-84.
6. Block G, Liss C, Reines S, Irr J, Nibbelink D. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. Eur Neurol 1997;37:23-7.
7. Männistö PT. Clinical potential of catechol-O-methyltransferase (COMT) inhibitors as adjuvants in Parkinson's disease. CNS Drugs 1994;1:172-9.
8. Zürcher G, Keller HH, Kettler R, Borgulya J, Bonetti EP, Eigenmann R, et al. Ro 40-7592, a novel, very potent, and orally active inhibitor of catechol-O-methyltransferase: a pharmacological study in rats. Adv Neurol 1990;53:497-503.
9. Da Prada M, Zürcher G, de Yebenes JG. Ro 40-7592, a potent inhibitor of the COMT in extracerebral tissue and brain: pharmacological studies in rats and monkeys. In: Agnoli A, editor. European conference on Parkinson's Disease and extrapyramidal disorders. Rome: J Libbey; 1990. p. 15.
10. Maj J, Rogóz Z, Skuza G, Sowinska H, Superata J. Behavioural and neurochemical effects of Ro 40-7592, a new COMT inhibitor with a potential therapeutic activity in Parkinson's disease. J Neural Transm Park Dis Dement Sect 1990;2:101-12.